Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.
Read Full NewsA trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.
Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.
Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.
Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.
The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.
A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.
1.
Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.
2.
Medicaid expansion tied to smaller declines in early-stage cancer detection
3.
When it comes to obesity-related cancers, where you shop for food matters
4.
SCOTUS Grapples With Multibillion-Dollar Lawsuits Over Roundup Cancer Claims
5.
enhancing survivors of brain tumors' quality of life.
1.
Liquid Biopsy in SCLC: cfDNA Profiling for Diagnosis and Treatment Monitoring
2.
Cold Antibody AIHA and Neoplastic Disorders: Unraveling the Clinical and Pathogenic Link
3.
An Introduction To The CA 15-3 Tumor Marker Test For Cancer Patients
4.
The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies
5.
Machine Learning in Genomic Analysis for Early Lung Cancer Detection: Key Advances and Insights
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
4.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge